¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

SCIE/JCR, Index Medicus/Medline, IBECS, IME


  • Factor de Impacto: 1,000(2015)
  • 5-años Factor de Impacto: 0,876
  • SCImago Journal Rank (SJR):0,24
  • Source Normalized Impact per Paper (SNIP):0,438
doi: 10.1016/S0009-739X(01)71908-2
Últimos avances en el campo del trasplante de islotes de Langerhans
Update in clinical islet transplantation
J. Arias Díaza, , J.L. Balibrea
Departamento de Cirugía. Hospital Clínico San Carlos
E. Vara
* Departamento de Bioquímica. Facultad de Medicina. Universidad Complutense. Madrid
Aceptado 31 mayo 2001

Las complicaciones tardías de la diabetes constituyen un importante problema de salud pública y hoy día está demostrado que se deben a que el tratamiento habitual con insulina inyectada proporciona un control inadecuado de la glucemia. En pacientes con diabetes tipo I, se puede conseguir un buen control glucémico mediante la terapia intensiva con insulina o mediante un trasplante de páncreas. La terapia intensiva con insulina no logra normalizar las cifras de hemoglobina glucosilada y presenta un riesgo considerable de crisis de hipoglucemia. El trasplante de páncreas proporciona un control metabólico excelente y, aunque sus resultados han mejorado espectacularmente durante la última década, continúa siendo un procedimiento invasivo y con una morbilidad significativa. El trasplante de islotes aislados representa la alternativa más lógica para el tratamiento de estos pacientes. En un estudio reciente, que utiliza un innovador régimen inmunosupresor, el trasplante de islotes se acompañó de una morbilidad irrelevante y logró en todos los pacientes un buen control metabólico con normalización de la hemoglobina glucosilada e independencia de la insulina mantenidas


The long-term complications of insulin-dependent diabetes mellitus have become a major health care problem, and it is now clear that they arise from inadequate homeostatic control of blood glucose by injected replacement insulin. In patients with type I diabetes, glycemic control can be achieved with intensive insulin therapy and pancreatic transplantation. Intensive insulin therapy does not normalize glycosilated hemoglobin values and may cause severe hypoglycemia. Pancreatic transplantation provides excellent glycemic control, and although the outcome of the procedure has improved dramatically over the past decade, it remains an invasive procedure with a substantial risk of morbidity. Transplantation of pancreatic islets is arguably the most logical approach to restoring metabolic homeostasis in people with diabetes. In a recent trial, using an improved immunosuppressive regimen, islet transplantation has been associated with a minimal risk of morbidity and uniformly resulted in good metabolic control, with normalization of glycosylated hemoglobin values and sustained freedom from the need for exogenous insulin

Palabras clave
Diabetes, Trasplante de islotes, Trasplante celular
Key words
Diabetes, Islet transplantation, Cell transplantation
El Texto completo solo esta disponible en PDF
A.M. Shapiro,J.R. Lakey,E.A. Ryan,G.S. Korbutt,E. Toth,G.I. Warnock
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
N Engl J Med, 343 (2000), pp. 230-238
F. Pattou,M.C. Vantyghem,C. Noel,J. Kerr-Conte,V. Gmyr,I. Martinache
Sequential intraportal islet allografts in immunosuppressed type I diabetic patients: preliminary results
Transplant Proc, 32 (2000), pp. 391-392
L. Luzi,G. Perseghin,M. Brendel,I. Terruzzi,A. Battezzati,M. Eckhard
Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type I diabetic patients
Diabetes, 50 (2001), pp. 277-282
P. Fiorina,P. Maffi,F. Bertuzzi,V. Di Carlo,G. Pozza,A. Secchi
Long term islet function could improve actuarial survival and cardiovascular outcome in uremic IDDM kidney transplanted patients
Acta Diabetologica, 37 (2001), pp. 151
D. De La Tour,T. Halvorsen,C. Demeterco,B. Tyrberg,P. Itkin-Ansari,M. Loy
Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo
Mol Endocrinol, 15 (2001), pp. 476-483
P. Salmon,J. Oberholzer,T. Occhiodoro,P. Morel,J. Lou,D. Trono
Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes
Mol Ther, 2 (2000), pp. 404-414
V. Gmyr,J. Kerr-Conte,S. Belaich,B. Vandewalle,E. Leteurtre,M.C. Vantyghem
Adult human cytokeratin 19-positive cells reexpress insulin promoter factor 1 in vitro: further evidence for pluripotent pancreatic stem cells in humans
Diabetes, 49 (2000), pp. 1671-1680
J. Kerr-Conte,F. Pattou,M. Lecomte-Houcke,Y. Xia,B. Boilly,C. Proye
Ductal cyst formation in collagen-embedded adult human islet preparations. A means to the reproduction of nesidioblastosis in vitro
Diabetes, 45 (1996), pp. 1108-1114
B. Soria,E. Roche,G. Berna,T. León-Quinto,J.A. Reig,F. Martín
Insulin- secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice
Diabetes, 49 (2000), pp. 157-162
N. Lenoir
Europe confronts the embryonic stem cell research challenge
Science, 287 (2000), pp. 1425-1427
P. Dupraz,S. Cottet,F. Hamburger,W. Dolci,E. Felley-Bosco,B. Thorens
Dominant negative MyD88 proteins inhibit interleukin-1 beta/interferon- gamma-mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells
J Biol Chem, 275 (2000), pp. 37672-37678
P. Dupraz,C. Rinsch,W.F. Pralong,E. Rolland,R. Zufferey,D. Trono
Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion
Gene Ther, 6 (1999), pp. 1160-1169
A. Bartkowiak,L. Canaple,I. Ceausoglu,N. Nurdin,A. Renken,L. Rindisbacher
New multicomponent capsules for immunoisolation
Ann N Y Acad Sci, 875 (1999), pp. 135-145
P. De Vos,J.F. Van Straaten,A.G. Nieuwenhuizen,M. De Groot,R.J. Ploeg,B.J. De Haan
Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?
Diabetes, 48 (1999), pp. 1381-1388
T.D. Zekorn,A. Horcher,U. Siebers,K. Federlin,R.G. Bretzel
Synergistic effect of microencapsulation and immunoalteration on islet allograft survival in bioartificial pancreas
J Mol Med, 77 (1999), pp. 193-198
P. De Vos,D. Vegter,B.J. De Haan,J.H. Strubbe,J.E. Bruggink,R. Van Schilfgaarde
Kinetics of intraperitoneally infused insulin in rats. Functional implications for the bioartificial pancreas
Diabetes, 45 (1996), pp. 1102-1107
G. Remuzzi,M. Rossini,O. Imberti,N. Perico
Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation
Lancet, 337 (1991), pp. 750-752
J. Arias Díaz,E. Vara,J.L. Balibrea,C. García,A. Marañés,A. Díaz
CT-guided fine needle approach for intrathymic islet transplantation in diabetic patients
Pancreas, 12 (1996), pp. 100-104
C.G. Groth,O. Korsgren,A. Tibell,J. Tollemar,E. Moller,J. Bolinder
Transplantation of porcine fetal pancreas to diabetic patients
Lancet, 344 (1994), pp. 1402-1404
F.H. Bach,J.A. Fishman,N. Daniels,J. Proimos,B. Anderson,C.B. Carpenter
Uncertainty in xenotransplantation: individual benefit versus collective risk
Nat Med, 4 (1998), pp. 141-144
K. Paradis,G. Langford,Z. Long,W. Heneine,P. Sandstrom,W.M. Switzer
Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue
Science, 285 (1999), pp. 1236-1241
Correspondencia: J. Arias Díaz. Servicio de Cirugía II. Hospital Clínico San Carlos. Ciudad Universitaria, s/n. 28040 Madrid
Copyright © 2001. Asociación Española de Cirujanos